Profund Advisors’s Maze Therapeutics MAZE Stock Holding History

Profund Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,016	Closed	-$249K	–	1316
2025 Q4	$249K	Buy	+6,016	New	+$207K	0.01%	1012

Other funds holding MAZE

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Profund Advisors's MAZE Position: Q1 2026 in Review

Profund Advisors sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 6,016 shares — an estimated $249K sold.

Profund Advisors first reported a position in MAZE in Q4 2025 and held it in 1 quarter. The position peaked at $249K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

Profund Advisors reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
Profund Advisors sold 6,016 Maze Therapeutics shares in Q1 2026, an estimated $249K.
Profund Advisors first reported a position in Maze Therapeutics in Q4 2025 and held it in 1 quarter.
Profund Advisors's Maze Therapeutics position peaked at $249K in Q4 2025.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.